@article{3088706,
    title = "The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma",
    author = "Hajek, R. and Siegel, D. and Orlowski, R.Z. and Ludwig, H. and Palumbo, A. and Dimopoulos, M.",
    journal = "Clinical Lymphoma Myeloma and Leukemia",
    year = "2014",
    volume = "55",
    number = "1",
    pages = "11-18",
    doi = "10.3109/10428194.2013.797084",
    keywords = "belinostat;  bortezomib;  dexamethasone;  doxorubicin;  entinostat;  histone deacetylase inhibitor;  lenalidomide;  melphalan;  mocetinostat;  panobinostat;  prednisone;  ricolinostat;  romidepsin;  thalidomide;  tubacin;  vorinostat, anemia;  bone marrow suppression;  cancer combination chemotherapy;  cancer survival;  diarrhea;  event free survival;  fatigue;  human;  monotherapy;  multiple myeloma;  nausea;  neutropenia;  overall survival;  peripheral neuropathy;  priority journal;  review;  thrombocytopenia, Animals;  Antineoplastic Agents;  Antineoplastic Combined Chemotherapy Protocols;  Drug Evaluation, Preclinical;  Histone Deacetylase Inhibitors;  Humans;  Multiple Myeloma;  Neoplasm Recurrence, Local;  Treatment Outcome",
    abstract = "Clinical outcomes for patients with multiple myeloma (MM) have improved substantially since the introduction of novel agents including the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide. However, most patients with MM eventually relapse, and prognosis remains poor among patients with relapsed and/or refractory disease. Combination therapy using agents with different mechanisms of action is emerging as an attractive treatment approach in oncology to increase efficacy and/or overcome resistance to standard treatment regimens. This review discusses unmet needs in the treatment of MM and the development of histone deacetylase inhibitors as a treatment modality for MM. © 2013 Informa UK, Ltd."
}